Our top pick for
Building a portfolio
Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around USD$805,000.
|52-week range||USD$1.15 - USD$3.0657|
|50-day moving average||USD$2.1951|
|200-day moving average||USD$1.9307|
|Wall St. target price||USD$5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.01|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$2 million|
|Return on assets TTM||-75.73%|
|Return on equity TTM||-151.3%|
|Market capitalisation||USD$45.9 million|
TTM: trailing 12 months
There are currently 335,651 Can-Fite BioPharma shares held short by investors – that's known as Can-Fite BioPharma's "short interest". This figure is 2.5% down from 344,092 last month.
There are a few different ways that this level of interest in shorting Can-Fite BioPharma shares can be evaluated.
Can-Fite BioPharma's "short interest ratio" (SIR) is the quantity of Can-Fite BioPharma shares currently shorted divided by the average quantity of Can-Fite BioPharma shares traded daily (recently around 2.0 million). Can-Fite BioPharma's SIR currently stands at 0.17. In other words for every 100,000 Can-Fite BioPharma shares traded daily on the market, roughly 170 shares are currently held short.
However Can-Fite BioPharma's short interest can also be evaluated against the total number of Can-Fite BioPharma shares, or, against the total number of tradable Can-Fite BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Can-Fite BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Can-Fite BioPharma shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Can-Fite BioPharma shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Can-Fite BioPharma.
Find out more about how you can short Can-Fite BioPharma stock.
We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.
Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.
Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $1.15 up to $3.0657. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.6062. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.